Methods applied to neonatal dried blood spot samples for secondary research purposes: a scoping review.

Zosia Miedzybrodzka, David J Porteous, Riccardo E Marioni, Sandosh Padmanabhan, Cathie L M Sudlow, Rona J Strawbridge, Rory Collins, Jill P Pell, Mads Melbye, Naveed Sattar, Jordan Canning, Matthew E Hurles

Journal: Critical reviews in clinical laboratory sciences 2024;61(8):685-708

PMID: 38855982

Abstract

This scoping review aimed to synthesize the analytical techniques used and methodological limitations encountered when undertaking secondary research using residual neonatal dried blood spot (DBS) samples. Studies that used residual neonatal DBS samples for secondary research (i.e. research not related to newborn screening for inherited genetic and metabolic disorders) were identified from six electronic databases: Cochrane Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, Medline, PubMed and Scopus. Inclusion was restricted to studies published from 1973 and written in or translated into English that reported the storage, extraction and testing of neonatal DBS samples. Sixty-seven studies were eligible for inclusion. Included studies were predominantly methodological in nature and measured various analytes, including nucleic acids, proteins, metabolites, environmental pollutants, markers of prenatal substance use and medications. Neonatal DBS samples were stored over a range of temperatures (ambient temperature, cold storage or frozen) and durations (two weeks to 40.5 years), both of which impacted the recovery of some analytes, particularly amino acids, antibodies and environmental pollutants. The size of DBS sample used and potential contamination were also cited as methodological limitations. Residual neonatal DBS samples retained by newborn screening programs are a promising resource for secondary research purposes, with many studies reporting the successful measurement of analytes even from neonatal DBS samples stored for long periods of time in suboptimal temperatures and conditions.

Address: School of Health & Wellbeing, University of Glasgow, Glasgow, UK.; School of Health & Wellbeing, University of Glasgow, Glasgow, UK.; Division of Cardiovascular Medicine, Karolinska Institute, Stockholm, Sweden.; Department of Medical Genetics, Ashgrove House, NHS Grampian, Aberdeen, UK.; Medical Genetics Group, School of Medicine, Medical Sciences, Nutrition and Dentistry, University of Aberdeen, Aberdeen, UK.; Centre for Genomic & Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; Danish Cancer Institute, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.; K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, Trondheim, Norway.; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK.; School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK.; Usher Institute, University of Edinburgh, Edinburgh, UK.; Health Data Research UK, London, UK.; Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.